Purespring launches for kidney therapies
2020; American Chemical Society; Volume: 98; Issue: 46 Linguagem: Inglês
10.1021/cen-09846-buscon14
ISSN2474-7408
Autores Tópico(s)Biomedical Ethics and Regulation
ResumoPurespring Therapeutics has launched with about $60 million in series A financing from the health-care investment firm Syncona to develop gene therapies focused on the kidney. Purespring is based on technology from Moin Saleem, a professor of pediatric renal medicine at the University of Bristol. It's Syncona's sixth gene therapy company since 2012. Biogen acquired one of them, Nightstar, last year for $877 million.
Referência(s)